Knight Therapeutics (KHTRF) Expected to Post Earnings on Thursday

Knight Therapeutics (OTCMKTS:KHTRF) is expected to release its results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $0.01 per share and revenue of $88.9650 million for the quarter.

Knight Therapeutics Stock Up 2.1%

Shares of KHTRF stock opened at $7.05 on Thursday. Knight Therapeutics has a 52-week low of $4.07 and a 52-week high of $7.40. The firm’s 50 day moving average price is $6.64 and its two-hundred day moving average price is $5.53.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada reissued an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.